Q-linea AB Stock

Equities

QLINEA

SE0011527845

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Stockholm 11:22:45 2024-04-18 am EDT 5-day change 1st Jan Change
2.04 SEK -1.45% Intraday chart for Q-linea AB -3.77% -44.86%
Sales 2024 * 60.55M 5.51M Sales 2025 * 167M 15.19M Capitalization 238M 21.71M
Net income 2024 * -191M -17.39M Net income 2025 * -146M -13.3M EV / Sales 2024 * 1.73 x
Net cash position 2024 * 133M 12.15M Net cash position 2025 * 5.88M 535K EV / Sales 2025 * 1.39 x
P/E ratio 2024 *
-1.68 x
P/E ratio 2025 *
-2.49 x
Employees 127
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.75%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.45%
1 week-3.77%
Current month-4.67%
1 month-7.69%
3 months-40.35%
6 months-33.55%
Current year-44.86%
More quotes
1 week
2.00
Extreme 2
2.13
1 month
2.00
Extreme 2
2.38
Current year
2.00
Extreme 2
3.86
1 year
2.00
Extreme 2
10.30
3 years
2.00
Extreme 2
164.00
5 years
2.00
Extreme 2
187.50
10 years
2.00
Extreme 2
187.50
More quotes
Managers TitleAgeSince
Founder 53 08-03-31
Director of Finance/CFO 70 23-04-30
Chief Operating Officer 55 21-12-31
Members of the board TitleAgeSince
Chairman 62 11-12-31
Founder 54 08-03-31
Director/Board Member 70 17-12-31
More insiders
Date Price Change Volume
24-04-18 2.04 -1.45% 61,593
24-04-17 2.07 -0.48% 61,332
24-04-16 2.08 +0.24% 18,495
24-04-15 2.075 -1.43% 15,755
24-04-12 2.105 -0.71% 12,827

Delayed Quote Nasdaq Stockholm, April 18, 2024 at 11:22 am EDT

More quotes
Q linea AB is a Sweden-based medical technology company. The Company develops and manufactures in-vitro diagnostic (IVD) solutions for infectious diseases. The Company's core product candidate is ASTar, a fully-automated instrument for Antibiotic Susceptibility Testing (AST). It measures bacteria's antimicrobial susceptibility using the disposables developed by the Company. It is able to provide a susceptibility profile within three to six hours directly from a positive blood culture, which enables early administration of antibiotics specifically targeting the disease-causing pathogen. Its main application is the identification of sepsis in hospital patients and the product is aimed primarily at hospital laboratories.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. QLINEA Stock